1. General introduction 28 11. Arno AI, Gauglitz GG, Barret JP, Jeschke MG. Up-to-date approach to manage keloids and hypertrophic scars: a useful guide. Burns. Nov 2014;40(7):1255-66. doi:S03054179(14)00071-0 [pii] 10.1016/j.burns.2014.02.011 12. Betarbet U, Blalock TW. Keloids: A Review of Etiology, Prevention, and Treatment. J Clin Aesthet Dermatol. Feb 2020;13(2):33-43. 13. Carswell L, Borger J. Hypertrophic Scarring Keloids. Jan 2023;doi:NBK537058 [bookaccession] 14. Chike-Obi CJ, Cole PD, Brissett AE. Keloids: pathogenesis, clinical features, and management. Semin Plast Surg. Aug 2009;23(3):178-84. doi:10.1055/s-0029-1224797 15. Lawrence JW, Mason ST, Schomer K, Klein MB. Epidemiology and impact of scarring after burn injury: a systematic review of the literature. J Burn Care Res. Jan-Feb 2012;33(1):136-46. doi:10.1097/BCR.0b013e3182374452 16. Lu W, Chu H, Zheng X. Effects on quality of life and psychosocial wellbeing in Chinese patients with keloids. Am J Transl Res. 2021;13(3):1636-1642. 17. Nakashima M, Chung S, Takahashi A, et al. A genome-wide association study identifies four susceptibility loci for keloid in the Japanese population. Nat Genet. Sep 2010;42(9):768-71. doi:ng.645 [pii] 10.1038/ng.645 18. Ogawa R, Watanabe A, Than Naing B, et al. Associations between Keloid Severity and Single-Nucleotide Polymorphisms: Importance of rs8032158 as a Biomarker of Keloid Severity. Journal of Investigative Dermatology. 2014/07/01/ 2014;134(7):2041-2043. doi:https://doi.org/10.1038/jid.2014.71 19. Huang J, Gong Y, Lin J-M, et al. TFCP2L1 as a potential diagnostic gene biomarker of Keloid given its association with immune cells-a study based on machine learning and RNA sequence. Alexandria Engineering Journal. 2024/04/01/ 2024;93:360-370. doi:https://doi.org/10.1016/j.aej.2024.02.043 20. Dong X, Mao S, Wen H. Upregulation of proinflammatory genes in skin lesions may be the cause of keloid formation (Review). Biomed Rep. Nov 2013;1(6):833-836. doi:br01-06-0833 [pii] 10.3892/br.2013.169
RkJQdWJsaXNoZXIy MTk4NDMw